Navigation Links
Beckman Coulter Announces First Quarter 2008 Results
Date:4/30/2008

een restated to correct these immaterial errors, as set forth in the following table:

Previously

Reported restated

Depreciation and amortization $54.6 $48.5

Change in inventories (27.0) (33.3)

Change in long-term lease receivables 4.9 4.0

Change in other (3.1) (2.2)

Net cash provided by operating activities 82.5 70.1

Additions to property, plant and equipment (76.9) (64.5)

Net cash used in investing activities (87.7) (75.3)

Change in Accounting for Convertible Debt Securities

Under a soon to be released Financial Accounting Standards Board ("FASB") Staff Position, convertible debt securities that may be settled in cash, including partial cash settlement, would be separated into debt and equity components. Interest expense will be recorded based upon the market rate at the date of issuance. This change in methodology, which will become effective for us as of the beginning of 2009, will be applied retrospectively to previously issued convertible debt instruments as well as to new instruments. The adoption of this new accounting rule is estimated to increase our 2008 and 2007 non-cash interest expense by approximately $13 million, resulting in a reduction of our diluted earning per share by approximately $0.13 in 2008 and $0.12 in 2007.

Non-GAAP Financial Measures

"GAAP" refers to financial information presented in accordance with generally accepted accounting principles in the United States.

To supplement the condensed consolidated financial statements and discussion presented on a GAAP basis, this press release includes non-GAAP financial measures with respect to the quarters
'/>"/>

SOURCE Beckman Coulter, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related biology technology :

1. Beckman Coulter Acquires Rights to Hepatitis C Virus
2. Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share
3. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
4. Beckman Coulter to Present at the 2008 Bear Stearns London Healthcare Conference
5. Beckman Coulter Releases the High-Volume UniCel(R) DxC 880i Integrated Work Cell
6. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
7. Beckman Coulter to Present at the JPMorgan Healthcare Conference
8. Beckman Coulter Elects AMN Healthcare Executive to Board of Directors
9. Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies
10. Beckman Coulter to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Beckman Coulter to Present at the 19th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...hed the Sixth Milestone in its Ofatumumab ...N, Denmark, October 10 /- G...d the sixth milestone for,ofatumumab (HuMax-CD20(R...SmithKline (GSK). A milestone payment of approxima...) was triggered by the first patient,receiving tre...
(Date:10/10/2008)...Oct. 10 /Xinhua-- Beike,Biotechnology...bal leader in,stem cell research and treatment thr...as signed eight separate mutual cooperation agreem...anding stem cell research organizations.,As part o...em Cell Expert,Advisory Committee" and a separate ...
(Date:10/10/2008)...RNewswire/ -- Twenty of Britain,s most,innovative ...bit their,ideas at the fifth annual SETsquared Par...eld at One Great George Street, London, from 8am o...m of technology innovators,in electronics, informa...Six companies will give 10-minute presentations to...
(Date:10/10/2008)...Newswire/ -- Takeda Pharmaceutical Company,Limited...earch and,Development Center, Inc., a wholly owned...ation that the U.S. Food and Drug Administration (...e alogliptin New Drug Application,(NDA) by the Pre...r 27,2008., "In our most recent discussion with ...
Breaking Biology Technology:Genmab Reaches Milestone in Ofatumumab Collaboration 2Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards 2Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards 3Creators of Britain's Innovation Economy to Showcase the Technologies of the Future at the Fifth SETsquared Partnership Showcase 2008 2Creators of Britain's Innovation Economy to Showcase the Technologies of the Future at the Fifth SETsquared Partnership Showcase 2008 3FDA Continues Review of Takeda's New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes 2
...er company looks to reclaim lost ground , ,CHIPPE... be operating out of offices on Lowater Road here ...hip to new and wonderful heights. , ,With its next... the company with the name in supercomputing is lo...orate eye that, just a few years ago, had nearly b...
...anced Research Projects Agency (DARPA), has awarde...Development under the DARPA Super High Efficienc...that could increase the funding to a total award o... in 1998, last week received a $4.6 million contra...inging their total dollars in new contracts and gr...
...the 1990s, it used to be that every company needed...foosball money could buy to launch their business....pany than to be one so you could attract great emp...ecame very profitable for companies like Herman Mi...nt companies. , ,Obviously, this has changed. Com...
...ays companies do business. , ,MADISON, WI- From o...World Wide Web and all it offers can equip busines...tomer satisfaction and, as a result, profits. It h... where companies use Internet-enabled technologies... deliver value to customers in entirely new ways. ...
Other Biology Technology:Cray Rides Again 2Cray Rides Again 3Alfalight Gets $3.8M From DARPA - Funding has increased to $8.5 Million 2The Top 10 Musts That Should Be in Your Business Survival Kit 2The Top 10 Musts That Should Be in Your Business Survival Kit 3Institute Helps Industries Enhance Business Strategies 2Institute Helps Industries Enhance Business Strategies 3Institute Helps Industries Enhance Business Strategies 4
(Date:10/10/2008)... previously unknown relationship between stem cell...ria a cell,s energy makers. Stem cells with more a... differentiate and are more likely to form tumors....could lead to methods of enriching the best stem c... provide some insights into the role of stem cells...
(Date:10/10/2008)...MADISON Governor Jim Doyle today announced a hist... institutions to advance personalized health care ...diseases. The Wisconsin Genomics Initiative is a c...Clinic, Medical College of Wisconsin (MCW), Univer...alth (UWSMPH) and UW-Milwaukee (UWM). , Wisconsi...
(Date:10/10/2008)...the 1950s, Austrian and Swiss scientists conducted...taking photographs of the glaciers, mountains and ...ist Fritz Mller spent eight months in the region a...raphing the Himalayan glaciers. , Now, fifty yea... these scientists are of immense value in trying t...
(Date:10/10/2008)...e in German . , DNA, the molecule that acts a...of life, is highly resistant against alteration by...m for its photostability presents some puzzling pr...e four chemical bases that make up the DNA molecul...n showing that DNA strands differ in their light s...
Breaking Biology News(10 mins):Governor Doyle announces historic genomic research collaboration 2'Himalaya -- Changing Landscapes' photo exhibition draws attention to the impacts of climate change 2'Himalaya -- Changing Landscapes' photo exhibition draws attention to the impacts of climate change 3Can genetic information be controlled by light? 2Marital Stress Linked to Heart Disease 4431 1Marital Stress Linked to Heart Disease 4431 2Marital Stress Linked to Heart Disease 4431 3Los Angeles Red Cross Aids Thousands of Wildfire Evacuees 4427 1Los Angeles Red Cross Aids Thousands of Wildfire Evacuees 4427 2Fires Put Pregnant Women Infants at Risk 4423 1Fires Put Pregnant Women Infants at Risk 4423 2Oncolytics Biotech Inc Announces Approval for U K Clinical Trial Investigating REOLYSIN 28R 29 in Combination with Cyclophosphamide 1450 1Oncolytics Biotech Inc Announces Approval for U K Clinical Trial Investigating REOLYSIN 28R 29 in Combination with Cyclophosphamide 1450 2Oncolytics Biotech Inc Announces Approval for U K Clinical Trial Investigating REOLYSIN 28R 29 in Combination with Cyclophosphamide 1450 3
...key role in mediating the outcome of competition b...ease-bearing conquistadors in the New World--or, o...bacteria to spread their viruses to competing bact...o different general ways in which bacteria compete...trategy seems to be particularly effective under d...
...sionals and the general public alike have been acu...ult from a flu pandemic. Although many people migh...is the infamous 1918-1920 pandemic--and the possib...he most trepidation. , Strangely, researchers s...this particular strain of the flu virus in that pa...
...m global warming? Perhaps, but the tradeoffs invol...ear waste generated each year and a greatly increa...sion of nuclear material into terrorists, hands. ...dney Ewing, who has analyzed just how much nuclear...reduce greenhouse gas emissions worldwide, and the...
...rategy for infecting cornea cells that may also ex...o a study by researchers at the University of Illi...appears in the Sept. 25 issue of the Journal of Ce...- HSV-1, the strain that causes cold sores on the ... cornea, the clear, domed surface that forms the e...
Other Biology News:Different strategies underlie the ecology of microbial invasions 2Recurrence of a flu pandemic similar to infamous 1918 flu could kill 62 million 2Recurrence of a flu pandemic similar to infamous 1918 flu could kill 62 million 3Plutonium or greenhouse gases? Weighing the energy options 2Study shows how herpes infects cornea, evades immune cells 2
Hybridization Buffer 3.6 ml
Mouse monoclonal [0.N.305] to G protein alpha - BSA and Azide free ( Abpromise for all tested applications). Antigen: Partially purified G protein alpha from rat brain. Entrez GeneID: 2778
Rabbit polyclonal to hCG ( Abpromise for all tested applications). entrezGeneID: 1081 SwissProtID: P01215
Glutathione Agarose Beads 10 ml
Biology Products: